108347-85-9

NMNH (reduced Nicotinamide Mononucleotide) is a new potent NAD+ precursor. It is a new form of NMN, can increase NAD levels to a much higher extent.
NMNH is a fluorescent molecule, in contrast to NMN. The molecular formulae for NMNH is C11H17N2O8P and it is also known as 1-(5-O-phosphono-beta-D-ribofuranosyl) -1,4-dihydropyridine-3-carboxamide  Reduced nicotinamide mononucleotide.

β-Nicotinamide mononucleotide, reduced form disodium (β-NMN) is the oxidized form of NAD+ precursor and is a NAD+ enhancer. β-Nicotinamide mononucleotide, reduced form disodium can be reduced to dihydronicotinamide mononucleotide (NMNH). NMNH inhibits glycolysis, TCA cycle, and cell growth[1].

β-Nicotinamide mononucleotide, reduced form disodium (β-NMN) is the oxidized form of NAD+ precursor and is a NAD+ enhancer. β-Nicotinamide mononucleotide, reduced form disodium can be reduced to dihydronicotinamide mononucleotide (NMNH). NMNH inhibits glycolysis, TCA cycle, and cell growth.

2-8°C

[1] Liu Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. J Proteome Res. 2021 May 7;20(5):2596-2606. DOI:10.1021/acs.jproteome.0c01037